Company intelligence / Profile preview

Tactogen

Palo Alto, California, United Statestactogen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Tactogen has developed several promising candidate compounds that are well tolerated in preclinical animal studies. These retain the key therapeutic effects of MDMA—such as increased self-compassion and reduced reactivity—without depleting serotonin or causing significant adverse events like blood pressure changes. The company aims to begin clinical trials soon, focusing first on safety and then efficacy for mental health indications such as PTSD. No human clinical results have been published yet.

Therapeutic areas: Psychiatry
Modalities: Small molecules (novel entactogens/empathogens; MDMA-like compounds)
Industry: Biotech

Drug pipeline

4 assets

TACT411

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tactogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tactogen.

Explore the full profile